Company Filing History:
Years Active: 2002
Title: Mark Taubman: Innovator in CD40 Signal Blocking Agents
Introduction
Mark Taubman is a notable inventor based in Larchmont, NY (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of CD40 signal blocking agents. His innovative work has led to the creation of a unique compound that has potential therapeutic applications.
Latest Patents
Mark Taubman holds a patent for a CD40 signal blocking agent. This agent comprises, as an active ingredient, an s-triazolo[1,5-a]pyrimidine derivative represented by a specific formula or a pharmaceutically acceptable salt thereof. This patent highlights his expertise in medicinal chemistry and his commitment to advancing healthcare solutions.
Career Highlights
Throughout his career, Mark has been associated with UCB S.A., a global biopharmaceutical company. His work at UCB has allowed him to focus on innovative treatments that address unmet medical needs. His dedication to research and development has positioned him as a key player in his field.
Collaborations
Mark has collaborated with esteemed colleagues such as Pierre P. Chatelain and Anne Mignot. These partnerships have fostered a collaborative environment that enhances the innovation process and leads to groundbreaking discoveries.
Conclusion
Mark Taubman's contributions to the field of pharmaceuticals, particularly through his patent on CD40 signal blocking agents, demonstrate his commitment to innovation and improving patient outcomes. His work continues to inspire future advancements in medical science.